Clinical study of combining arsenic trioxide (As2O3), all-trans retinoic acid (ATRA) and idarubicin (IDA) for induction therapy on the patients with relapsed acute promyelocytic leukemia(APL)

被引：0
|
作者：
Ma, J. [1 ]
Liu, J. [1 ]
Zhang, B. [1 ]
Zhan, Z. [1 ]
Jin, M. [1 ]
Wang, L. [1 ]
Gong, T. [1 ]
Shao, X. [1 ]
机构：
[1] Harbin Inst Hematol & Oncol, Harbin, Peoples R China
来源：
EJC SUPPLEMENTS | 2005年 / 3卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：284 / 284
页数：1
相关论文
共 50 条
  • [1] Clinical observations on arsenic trioxide (As2O3) and all-trans retinoic acid (ATRA) in the treatment of acute promyelocytic leukemia (APL).
    Ma, J
    Liu, JW
    Chen, LY
    Liang, H
    Zhang, Y
    BLOOD, 1998, 92 (10) : 483A - 483A
  • [2] Clinical observation on the efficacy of all-trans retinoic acid (ATRA) combined with arsenic trioxide (As2O3) in newly diagnosed acute promyelocytic leukemia (APL).
    Liu, YF
    Shen, ZX
    Hu, J
    Zhu, YM
    Li, JM
    You, JH
    Shen, Y
    Shi, ZZ
    Chen, SJ
    Chen, Z
    Wang, ZY
    BLOOD, 2004, 104 (11) : 253A - 254A
  • [3] Mechanisms of action and resistance to all-trans retinoic acid (ATRA) and arsenic trioxide (As2O3) in acute promyelocytic leukemia
    Akihiro Tomita
    Hitoshi Kiyoi
    Tomoki Naoe
    International Journal of Hematology, 2013, 97 : 717 - 725
  • [4] Mechanisms of action and resistance to all-trans retinoic acid (ATRA) and arsenic trioxide (As2O3) in acute promyelocytic leukemia
    Tomita, Akihiro
    Kiyoi, Hitoshi
    Naoe, Tomoki
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2013, 97 (06) : 717 - 725
  • [5] Clinical outcomes and rates of molecular remission with all-trans retinoic acid (ATRA) and arsenic trioxide (As2O3) combination therapy in newly diagnosed acute promyelocytic leukemia (APL).
    Tsirriberidou, A. M.
    Kantarjian, H. M.
    Garcia-Manero, G.
    Koller, C.
    Jones, D. M.
    Keating, M. J.
    Estey, E.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 337S - 337S
  • [6] Combination therapy with arsenic trioxide (ATO), all-trans retinoic acid (ATRA), and gemtuzumab ozogamycin (GO) in relapsed acute promyelocytic leukemia (APL).
    Aribi, A. M.
    Kantarjian, H.
    Estey, E.
    Freireich, E.
    Koller, C.
    Thomas, D.
    Kornblau, S.
    Faderl, S.
    Laddie, N.
    Garcia-Manero, G.
    Cortes, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 351S - 351S
  • [7] Arsenic trioxide (AS2O3) therapy for relapsed acute promyelocytic leukemia (APL):: Comparison with a historic control combining all-traps retinoic acid (ATRA) plus intensive chemotherapy
    Thomas, X
    Pigneux, A
    Raffoux, E
    Huguet, F
    Caillot, D
    Guerci, A
    Stamatoullas, A
    Reman, O
    Isnard, F
    Dreyfus, F
    Gratecos, N
    Bernard, M
    Arkam, Y
    Fenaux, P
    BLOOD, 2005, 106 (11) : 263A - 263A
  • [8] Tamibarotene Compared to All-Trans Retinoic Acid (ATRA) As Add-on to Arsenic Trioxide (ATO) in Subjects with Relapsed Acute Promyelocytic Leukemia (APL)
    Wang, Jianxiang
    Mi, Yingchang
    Jiang, Bin
    Chen, Xiequn
    Ji, Chunyan
    Li, Yan
    Zhao, Xielan
    Lai, Yongrong
    Hu, Yu
    Tang, Aiping
    Liu, Ting
    Jin, Jie
    Li, Junmin
    Yang, Linhua
    Li, Jinyong
    Meng, Fanyi
    BLOOD, 2015, 126 (23)
  • [9] All-trans retinoic acid (ATRA) and arsenic trioxide (As2O3) combination therapy induces high rates of durable molecular remission in newly diagnosed acute, promyelocytic leukemia (APL)
    Tsimberidou, Apostolia-Maria
    Kantarjian, Hagop
    O'Brien, Susan
    Garcia-Manero, Guillermo
    Koller, Charles
    Jones, Daniel
    Pierce, Sherry
    Brandt, Mark
    Keating, Michael
    Estey, Estey
    BLOOD, 2007, 110 (11) : 543A - 543A
  • [10] A 3-year follow-up of all-trans retinoic acid (ATRA) and arsenic trioxide (As2O3) as front line therapy for newly diagnosed acute promyelocytic leukemia (APL)
    Hu, J
    Liu, YF
    Zhu, YM
    Shi, ZZ
    Li, JM
    Wang, L
    Chen, Y
    Shen, ZX
    BLOOD, 2005, 106 (11) : 260A - 260A
12345